Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
The awards were made on
Zogenix (Nasdaq:ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options but face a critical need. For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Media: David Polk
Senior Media Relations Strategist, Syneos Health
310-309-1029 | firstname.lastname@example.org
Source: Zogenix, Inc.